Last reviewed · How we verify
AZD4144
AZD4144 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
AZD4144 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).
At a glance
| Generic name | AZD4144 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PI3K delta and PI3K gamma inhibitor |
| Target | PI3K delta and PI3K gamma |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, AZD4144 is thought to modulate immune cell function and potentially treat various conditions. However, the exact mechanism of action is still being researched.
Approved indications
- Relapsed or refractory chronic lymphocytic leukemia (CLL)
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. (PHASE2)
- A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease. (PHASE1)
- A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity (PHASE1)
- A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants (PHASE1)
- A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants (PHASE1)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants (PHASE1)
- A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants (PHASE1)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD4144 CI brief — competitive landscape report
- AZD4144 updates RSS · CI watch RSS
- AstraZeneca portfolio CI